

ASX:CXO Announcement

16 May 2022

Change of Director's Interest

Advanced Australian lithium developer, Core Lithium Ltd (Core or Company) (ASX: CXO), includes an Appendix 3Y for director Stephen Biggins. The notice shows the exercise of unquoted performance rights and options previously approved by shareholders and the sale of shares to pay for tax and other expenses. There are no further performance rights or options capable of exercise at this time and Stephen Biggins beneficial interest has increased from 3,206,347 shares to 5,076,000 shares.

This announcement has been approved for release by the Core Lithium Board.

For further information please contact:

Stephen Biggins
Managing Director
Core Lithium Limited
+61 8 8317 1700
info@corelithium.com.au

For Media and Broker queries:

Fraser Beattie
Account Manager
Cannings Purple
+61 421 505 557
fbeattie@canningspurple.com.au

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity | Core Lithium Ltd |
|----------------|------------------|
| ABN | 80 146 287 809 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Stephen BIGGINS |
|---------------------|------------------------|
| Date of last notice | 26 November 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Indirect | |
|--|--|--|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Mr Biggins is a director of and has a beneficial interest in the registered holder Nowak Investments Pty Ltd ATF The Nowak Superannuation Fund (Nowak) 2. Mr Biggins is a director of and has | |
| | a beneficial interest in the registered holder Genex Resources Pty Ltd ATF Biggins Resources Family Trust (Genex) | |
| Date of change | From 10 May 2022 to 13 May 2022 inclusive. | |

01/01/2011 Appendix 3Y Page 1

⁺ See chapter 19 for defined terms.

| No of convities hold writer to shares | 070 (00 Chayea hald less Nessel |
|--|--|
| No. of securities held prior to change | 979,680 Shares held by Nowak |
| | 2,226,667 Shares held by Genex |
| | 7,250,000 Performance Rights expiring at various times to 30 June 2026 held by Genex. |
| | 2,166,666 vested Performance Rights expiring at 30 June 2023 held by Genex. |
| | 2,031,666 vested Performance Rights expiring at 30 June 2024 held by Genex. |
| | 5,000,000 Options held by Genex |
| Class | Shares - Fully paid ordinary shares. |
| | Performance Rights – unquoted performance rights subject to satisfaction of performance conditions. |
| | Options - unquoted options with an exercise price of 6.0 cents each and expiry of 30 June 2023. |
| Number acquired | 4,198,332 Shares on exercise of vested Performance Rights held by Genex 5,000,000 Shares on exercise of Options held by Genex |
| Number disposed | 3. 913,680 Shares held by Nowak 4. 6,414,999 Shares held by Genex |

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

| Value/Consideration | 1. \$Nil paid for Shares on exercise of | |
|---|---|--|
| Note: If consideration is non-cash, provide details and estimated valuation | Performance Rights | |
| | 2. \$300,000 paid for Shares on | |
| | exercise of Options | |
| | 3. \$1,027,067.40 received on sale of | |
| | Shares held by Nowak | |
| | 4. \$7,250,952.61 received on sale of | |
| | Shares held by Genex | |
| | | |
| No. of securities held after change | 66,000 Shares held by Nowak | |
| | , , , , , , , , , , , , , , , , , , , | |
| | 5,010,000 Shares held by Genex | |
| | • | |
| | 7,250,000 unvested Performance Rights | |
| | expiring at various times to 30 June 2026 | |
| | held by Genex. | |
| | - | |
| Nature of change | 1. Exercise of vested Performance | |
| Example: on-market trade, off-market trade, exercise of options, issue | Rights | |
| of securities under dividend reinvestment plan, participation in buy- back | 2. Exercise of Options | |
| Data | 3. Sale of Shares on-market | |
| | 4. Sale of Shares on-market | |
| | 1. Sale of Shares on-market | |
| | | |

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | Not applicable |
|--|----------------|
| | |
| Nature of interest | |
| | |
| | |
| Name of registered holder | |
| (if issued securities) | |
| (A. 100 de | |
| Date of change | |
| • | |
| No. and class of securities to which | |
| interest related prior to change | |
| Note: Details are only required for a contract in | |
| relation to which the interest has changed | |
| Laboration 2 and | |
| Interest acquired | |
| | |
| Interest disposed | |
| • | |
| | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and an estimated valuation | |
| and an estimated valuation | |
| Interest after change | |

Part 3 - +Closed period

| Were the interests in the securities or contracts detailed | Not applicable |
|---|----------------|
| above traded during a +closed period where prior written | |
| clearance was required? | |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

Appendix 3Y Page 4 01/01/2011

⁺ See chapter 19 for defined terms.